Add to Favorites Newsroom RSS Share
fb-shareMoffitt Cancer Center
Tampa, FL USA

Our News on Newswise

New Drug Combination Shows Promising Activity in Non-Small Cell Lung Cancer Patients

Patients with non-small cell lung cancer (NSCLC) now have more improved treatment options compared to standard of care with the addition of several new agents called immune-checkpoint inhibitors (ICI). Despite these changes, many patients still...
27-Aug-2019 9:00 AM EDT Add to Favorites

Moffitt Researchers Develop Model to Personalize Radiation Treatment for Breast Cancer Patients

A personalized approach to cancer treatment has become more common over the last several decades, with numerous targeted drugs approved to treat particular tumor types with specific mutations or patterns. However, this same personalized strategy has...
22-Aug-2019 10:50 AM EDT Add to Favorites

Moffitt Researchers Complete Largest Genomic Analysis of Merkel Cell Carcinoma Patients

Merkel cell carcinoma (MCC) is a rare, aggressive skin tumor that is diagnosed in approximately 2,000 people each year in the United States. Since MCC affects so few people, it is difficult to study the genetic factors that lead to its development...
20-Aug-2019 10:30 AM EDT Add to Favorites

Moffitt Researchers Discover Possible New Treatment Strategy for Lung Cancer

Lung cancer is the second most common cancer found in both men and women. It is estimated there will be roughly 228,000 new lung cancer cases this year, and nearly 30% of those patients will have mutations in the KRAS pathway. This type of mutation...
19-Aug-2019 2:00 PM EDT Add to Favorites

Moffitt Researchers Identify Subtypes of Squamous Cell Lung Cancer

Despite improved knowledge of the molecular alterations in SCC, little is understood about how the alterations contribute to the development of the cancer and how potential vulnerabilities could be exploited to treat the disease. Researchers in...
8-Aug-2019 10:00 AM EDT Add to Favorites

Despite Treatment, Elderly Cancer Patients Have Worse Outcomes if HIV-Positive

Elderly cancer patients who are HIV-positive, particularly those with prostate and breast cancers, have worse outcomes compared to cancer patients in the same age range who do not have HIV. A Moffitt Cancer Center researcher, in collaboration with...
1-Aug-2019 11:05 AM EDT Add to Favorites

Moffitt Research of Selinexor for Relapsed/Refractory Multiple Myeloma Facilitates Recent FDA Approval

A first-in-class drug recently granted accelerated approval by the U.S. Food and Drug Administration (FDA) for adult patients with heavily pretreated multiple myeloma has been the subject of study at Moffitt Cancer Center for years. Now, selinexor...
24-Jul-2019 11:15 AM EDT Add to Favorites

Therapeutic Strategies Based on Evolutionary Principles May Be Key to Improving Patient Outcomes

In a new article published by Cancer Research, Moffitt Cancer Center researchers propose the evolutionary dynamics of background extinctions suggest this focus on finding new and better drugs may have neglected opportunities to develop new and...
9-Jul-2019 10:05 AM EDT Add to Favorites


see all news

Our Experts on Newswise

Newswise: AnnaGiuliano_Euroginopeningtalk_2017.jpg

Moffitt Cancer Center HPV Expert Kicked Off EUROGIN Conference

Anna Giuliano, Ph.D., director of Moffitt Cancer Center’s Center for Infection Research in Cancer, delivered the opening keynote address at the 2017 European Research Organization on Genital Infection and Neoplasia (EUROGIN) International...
10-Oct-2017 10:05 AM EDT

see all experts

Our YouTube Videos

About

Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 50 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt is a Top 10 cancer hospital and has been nationally ranked by U.S. News & World Report since 1999. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 6,000 team members, Moffitt has an economic impact in the state of $2.5 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter and YouTube.

Contacts

Kim Polacek
Senior Public Relations Account Coordinator

Kim.Polacek@Moffitt.org

813-745-7408

Steven Blanchard
Public Relations Account Coordinator

Steven.Blanchard@Moffitt.org

813-745-1718

Sara Bondell
Public Relations Account Coodinator

Sara.Bondell@moffitt.org

813-745-1353

Patty Kim
Public Relations Manager

Patty.Kim@Moffitt.org

813-745-7322

Twitter twitter-icon

Chat now!